Roger Song
Stock Analyst at Jefferies
(3.83)
# 688
Out of 5,139 analysts
49
Total ratings
47.62%
Success rate
12.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $37.68 | +221.13% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $33.40 | +34.73% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $7.68 | +108.33% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $464.93 | +21.31% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.41 | +254.61% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.71 | +2,299.10% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $40.53 | -11.18% | 1 | Aug 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $39.41 | +37.02% | 3 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Buy | $31 → $6 | $7.04 | -14.77% | 2 | Jul 22, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Buy | $6 | $1.36 | +341.18% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $4.58 | +52.84% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $285.04 | -14.05% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $13.65 | +90.48% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $20.16 | -65.28% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.46 | +230.97% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $2.62 | +167.18% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $70.93 | +25.48% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $8.01 | +212.11% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $19.21 | +113.43% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $20.16 | +73.61% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $46.59 | +176.88% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $5.39 | +48.42% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $104.26 | -6.96% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $33.92 | +224.29% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $4.24 | +725.47% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.81 | +397.24% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $8.05 | -0.62% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $13.82 | +1,419.54% | 1 | Sep 2, 2020 |
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $37.68
Upside: +221.13%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $33.40
Upside: +34.73%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $7.68
Upside: +108.33%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $464.93
Upside: +21.31%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.41
Upside: +254.61%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.71
Upside: +2,299.10%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $40.53
Upside: -11.18%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $39.41
Upside: +37.02%
Replimune Group
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $7.04
Upside: -14.77%
Akebia Therapeutics
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.36
Upside: +341.18%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $4.58
Upside: +52.84%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $285.04
Upside: -14.05%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $13.65
Upside: +90.48%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $20.16
Upside: -65.28%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.46
Upside: +230.97%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $2.62
Upside: +167.18%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $70.93
Upside: +25.48%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $8.01
Upside: +212.11%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $19.21
Upside: +113.43%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $20.16
Upside: +73.61%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $46.59
Upside: +176.88%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $5.39
Upside: +48.42%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $104.26
Upside: -6.96%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $33.92
Upside: +224.29%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $4.24
Upside: +725.47%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $1.81
Upside: +397.24%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $8.05
Upside: -0.62%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $13.82
Upside: +1,419.54%